REDWOOD CITY, Calif. & BOSTON– Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appointment of Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer. Dr. Boman will spearhead Adicet’s regulatory strategy to further advance existing and new pipeline opportunities for the Company’s gamma delta T cell platform.
“We are incredibly excited to welcome Nancy to the Adicet team,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “Her vast experience in successfully filing marketing applications for more than 15 products, including in hematologic malignancies, such as non-Hodgkin’s lymphoma, is perfectly aligned with our plan to initiate a potentially pivotal program for ADI-001 in the first half of 2023. Nancy’s leadership in building and expanding global regulatory operations particularly in the oncology field, including in solid tumors, is an asset to the team and positions us well as we expect to submit an IND application for ADI-925 in the second half of 2023 and potentially advance other pipeline programs, as disclosed in our recent R&D event, to regulatory submissions and clinical trials.”
“I am pleased to join the Adicet team during this pivotal time in the Company’s growth trajectory,” commented Dr. Boman, Senior Vice President and Chief Regulatory Officer of Adicet Bio. “With the positive updates on ADI-001 to date and an emerging preclinical pipeline of potentially best-in-class gamma delta T cell therapy product candidates, I look forward to supporting the team in bringing novel therapies to patients in need.”
Dr. Boman has nearly 30 years of industry experience in the biotech and pharmaceutical industry with expertise in clinical development, chemistry, manufacturing and controls management, and regulatory operations leading more than 15 drug marketing applications. She joins Adicet from Encoded Therapeutics, Inc., where, as a Chief Regulatory Officer, she built and oversaw all aspects of the regulatory department for its gene therapy candidates. Previously, Dr. Boman led the regulatory affairs practice as Chief Regulatory Officer at AveXis Inc. (now Novartis Gene Therapies), helping manage product candidate Zolgensma®, as well as expand the commercialization of adeno-associated virus-based innovative gene therapies. Prior to that she served as Senior Vice President, Regulatory Affairs and Pharmacovigilance at Alder BioPharmaceuticals, Inc., and has also held positions in regulatory affairs and clinical development at Cell Therapeutics, Inc., Genentech, Inc. and Amgen, Inc. Dr. Boman received her M.D. in Human Medicine, her Ph.D. in Biochemistry, and B.Sc. in General Science from The University of British Columbia.
